Mirjam K. de Vries

Decreased clinical response to infliximab in ankylosing spondylitis is correlated with anti-infliximab formation

Mirjam K. de Vries, Steven O. Stapel, Henk de Vrieze et al. · Annals of the Rheumatic Diseases · 2007 · 155 citations · Full text

Medicine, Pharmacology, Pharmacotherapy +13

Immunogenicity does not influence treatment with etanercept in patients with ankylosing spondylitis

Mirjam K. de Vries, Irene E. van der Horst‐Bruinsma, Michael T. Nurmohamed et al. · Annals of the Rheumatic Diseases · 2008 · 137 citations · Full text

Medicine, Immunology, Pharmacotherapy +13

Erythrocyte sedimentation rate, C‐reactive protein level, and serum amyloid A protein for patient selection and monitoring of anti–tumor necrosis factor treatment in ankylosing spondylitis

Mirjam K. de Vries, I C van Eijk, Irene van der Horst‐Bruinsma et al. · Arthritis Care & Research · 2009 · 133 citations · Full text

Medicine, Immunology, Internal Medicine +13

Improvement of lipid profile is accompanied by atheroprotective alterations in high‐density lipoprotein composition upon tumor necrosis factor blockade: A prospective cohort study in ankylosing spondylitis

I C van Eijk, Mirjam K. de Vries, J.H.M. Levels et al. · Arthritis & Rheumatism · 2009 · 112 citations

Medicine, Pharmacology, Pharmacotherapy +16

Tuberculosis Risk in Ankylosing Spondylitis, Other Spondyloarthritis, and Psoriatic Arthritis in Sweden: A Population‐Based Cohort Study

Mirjam K. de Vries, Elizabeth V. Arkema, Jerker Jonsson et al. · Arthritis Care & Research · 2017 · 19 citations · Full text

Medicine, Clinical Sciences, Internal Medicine +17